Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Covaxin was earlier approved for children 12-18 years of age
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Subscribe To Our Newsletter & Stay Updated
